Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Xenetic Biosciences, a developer of biologic drugs and vaccines, has received a notice of allowance (NOA) of a patent application for its co-delivery technology in the US.
Subscribe to our email newsletter
The patent provides protection for co-delivery technology that is used in the company’s ImuXen product range.
The patent covers a method which deals with packaging a protein vaccine together with a plasmid DNA that encodes the vaccine, in the same liposome and regardless of the liposome size for genetic immunisation.
This ensures that both, the protein vaccine and the DNA encoding the vaccine are delivered simultaneously (co-delivery) in the same antigen presenting cells.
The company already has patents granted in relation to this technology in Europe, Russia and China as well as separate patents that cover their polysaccharide based vaccines.